PegBio Co., Ltd. Class H

As of December 31, 2025, PegBio Co., Ltd. Class H carries a market capitalization of 26.99B, placing it among publicly traded companies globally. Its enterprise value stands at 26.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PegBio Co., Ltd. Class H's next confirmed earnings release is scheduled for March 23, 2027.

As of December 31, 2025, PegBio Co., Ltd. Class H has 391.09M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, PegBio Co., Ltd. Class H maintains a current ratio of 3.94, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, PegBio Co., Ltd. Class H's stock has declined approximately 93.76% over the past 52 weeks. The 50-day moving average sits at 5.36, while the 200-day moving average is 28.05.

As of December 31, 2025, PegBio Co., Ltd. Class H holds 580.94M in cash and equivalents against 104.17M in total debt, resulting in a net debt position of -425.76M. Total book value stands at 499.12M, with working capital of 462.10M providing operational flexibility.